ValeurQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFrais de vente, généraux et administratifs35.1 M41.8 M41.91 M39.82 M43.46 M49.23 M174.41 MRecherche et développement4.92 M7.26 M6.73 M6.32 M7.25 M8.1 M28.41 MRésultat d'exploitation18.48 M-12.79 M-2.03 M3.45 M22.41 M-8.06 M15.77 MTotal des produits hors exploitation1.48 M1.55 M1.48 M1.62 M1.69 M1.76 M6.55 MCharges d'intérêts, nettes des intérêts capitalisés154 K153 K157 K158 K162 K160 K637 KRésultat hors exploitation, hors charges d'intérêts1.41 M1.5 M1.34 M1.49 M1.56 M1.53 M5.93 MRevenus/dépenses exceptionnels70 K42 K-24 K-26 K-36 K71 K-15 KRésultat avant impôts19.95 M-11.4 M-710 K4.92 M17.38 M-6.46 M15.12 MPart des actionnaires dans le résultat———————Impôts148 K———-2.65 M——Intérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts-18 K-4 000-5 00017 K-21 K-21 K-30 KRésultat net avant activités abandonnées19.81 M-11.25 M-553 K5.07 M23.24 M-6.3 M21.46 MActivités abandonnées———————Résultat net19.81 M-11.25 M-553 K5.07 M23.24 M-6.3 M21.46 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires19.81 M-11.25 M-553 K5.07 M23.24 M-6.3 M21.46 MBénéfice par action de base (BPA de base)0.41-0.23-0.010.10.47-0.120.44Bénéfice par action dilué (BPA dilué)0.4-0.23-0.010.10.46-0.120.43Nombre moyen d'actions de base en circulation48.85 M49.91 M50.37 M50.49 M50.34 M50.77 M—Nombre d'actions en circulation après dilution51.68 M49.91 M50.37 M51.91 M52.15 M50.77 M—EBITDA19.96 M-10.11 M797 K6.39 M25.5 M-4.8 M27.9 MEBIT18.48 M-12.79 M-2.03 M3.45 M22.41 M-8.06 M15.77 MCoût des ventes16.88 M16.32 M16.63 M17.92 M19.79 M19.16 M73.49 MAutres coûts des ventes—————173 K—Amortissements (flux de trésorerie)1.48 M2.69 M2.83 M2.94 M3.09 M3.27 M12.13 M
Vericel Corporation - Common Stock
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.
In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.